Readystate Asset Management LP Has $1.73 Million Stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Readystate Asset Management LP raised its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 97.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 169,819 shares of the company’s stock after acquiring an additional 83,700 shares during the quarter. Readystate Asset Management LP owned approximately 0.46% of iTeos Therapeutics worth $1,734,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in iTeos Therapeutics by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 1,500,602 shares of the company’s stock valued at $20,468,000 after purchasing an additional 9,660 shares during the last quarter. Public Employees Retirement System of Ohio lifted its stake in shares of iTeos Therapeutics by 4.9% in the 1st quarter. Public Employees Retirement System of Ohio now owns 39,003 shares of the company’s stock valued at $532,000 after acquiring an additional 1,817 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of iTeos Therapeutics by 4.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 121,250 shares of the company’s stock valued at $1,799,000 after acquiring an additional 5,409 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of iTeos Therapeutics by 35.9% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,998 shares of the company’s stock valued at $178,000 after acquiring an additional 3,172 shares in the last quarter. Finally, Panagora Asset Management Inc. grew its position in iTeos Therapeutics by 8.9% during the 2nd quarter. Panagora Asset Management Inc. now owns 131,553 shares of the company’s stock worth $1,952,000 after acquiring an additional 10,787 shares during the last quarter. 97.16% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently commented on ITOS shares. JPMorgan Chase & Co. cut their price target on iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. HC Wainwright reiterated a “buy” rating and issued a $46.00 price objective on shares of iTeos Therapeutics in a report on Friday, November 15th. Wells Fargo & Company assumed coverage on shares of iTeos Therapeutics in a report on Tuesday, August 13th. They issued an “overweight” rating and a $31.00 price objective for the company. Finally, Wedbush reiterated an “outperform” rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a report on Tuesday, November 12th.

iTeos Therapeutics Trading Down 1.8 %

Shares of NASDAQ ITOS opened at $8.19 on Thursday. The company has a 50 day simple moving average of $9.01 and a 200 day simple moving average of $13.42. iTeos Therapeutics, Inc. has a 1 year low of $7.54 and a 1 year high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last announced its earnings results on Tuesday, November 12th. The company reported ($1.05) EPS for the quarter, beating the consensus estimate of ($1.18) by $0.13. As a group, research analysts expect that iTeos Therapeutics, Inc. will post -3.46 EPS for the current fiscal year.

Insider Activity at iTeos Therapeutics

In related news, CFO Matthew Gall bought 5,000 shares of iTeos Therapeutics stock in a transaction that occurred on Tuesday, November 19th. The shares were acquired at an average cost of $7.73 per share, for a total transaction of $38,650.00. Following the completion of the acquisition, the chief financial officer now directly owns 65,429 shares of the company’s stock, valued at approximately $505,766.17. The trade was a 8.27 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 12.50% of the stock is currently owned by company insiders.

iTeos Therapeutics Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.